ArticleBMC neurology2026
Late-onset severe axonal polyneuropathy in mut0 methylmalonic acidemia after liver-kidney transplantation: a genotype-informed case report.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundLiver-kidney transplantation in methylmalonic acidemia (MMA) improves metabolic control but does not eliminate neurological risk. Peripheral neuropathy is increasingly recognized in transplanted patients, yet its pathophysiology and surveillance strategies remain poorly defined. CASE PRESENTATION: We describe a severe axonal sensorimotor polyneuropathy that occurred 12 years after combined liver and kidney transplantation in a 20-year-old patient with mut0 methylmalonic acidemia (MMA), compound heterozygous for MMUT gene mutations and lacking fibroblast MCM enzymatic activity. Clinical, electrophysiological, and biochemical investigations were performed, including cerebrospinal fluid analysis, anti-ganglioside antibody testing, and measurement of circulating biomarkers of neuroaxonal injury (NfL) and mitochondrial dysfunction (FGF21, GDF15). Electrophysiological studies demonstrated a purely axonal process with active denervation. Cerebrospinal fluid protein and cell count were normal, anti-ganglioside antibodies were negative, and neuroimaging was unremarkable, excluding Guillain-Barré syndrome variants. Plasma NfL was markedly elevated (4083 pg/mL, 204× ULN), exceeding levels reported in hereditary and acquired neuropathies. FGF21 (1682 pg/mL) and GDF15 (1438 pg/mL) indicated mitochondrial stress.
conclusionsThis case demonstrates that neurological stability is not guaranteed in mut0 MMA even 12 years post-transplantation. Management included switching from tacrolimus to everolimus and optimizing vitamin B12 supplementation. We propose NfL, FGF21, and GDF15 as monitoring tools for MMA transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.